-
Something wrong with this record ?
Statin adherence improves with age and subsequent treatment sequences: A retrospective cohort study using Proportion of Days Covered (PDC)
A. Tichopád, G. Donin, J. Žigmond, J. Ráfl, M. Rybář, P. Šedová, M. Vrablík
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Medication Adherence * MeSH
- Adult MeSH
- Dyslipidemias * drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors * therapeutic use MeSH
- Age Factors MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND: Dyslipidaemia is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), necessitating effective statin therapy. Despite statins' proven safety and efficacy, adherence remains suboptimal, with significant gaps between clinical practice and guideline recommendations. METHODS: This retrospective cohort study analysed anonymized health administrative claims data from six employee health funds in the Czech Republic, covering approximately 40% of the insured population from January 1, 2017, to December 31, 2020. We identified statin-incident as well as prevalent cohort of patients. Adherence to statin therapy was assessed using the proportion of days covered (PDC) metric, with factors such as age, gender, sequence of use, and treatment intensity considered as modifiers. RESULTS: Among the statin-prevalent cohort (SP, n = 890,180), 83.5% achieved a PDC ≥ 50%, and 61.0% reached a PDC ≥ 80%. In the statin-incident cohort (SI, n = 287,871), a clear trend of increasing adherence with age and medication sequence was observed: in adults aged 18-39 median PDC rose from 84.1% (IQR: 57-100) in the first to 94.7% (IQR: 75.6-100) in the third sequence; in those aged 80 + median PDC rose from 95.0% (IQR: 68.9-100) in the first to 100% (IQR: 78.3-100) in the third sequence. Logistic regression identified age (OR=1.011 per year), female gender (OR=0.896), high-intensity treatment (OR=0.975), and second (OR=1.267) or later treatment sequences (OR=1.704) as significant predictors of adherence (all p < 0.001). CONCLUSION: Adherence to statin therapy improves with subsequent treatment sequences and age. These findings highlight the need for targeted interventions to enhance adherence, particularly among younger patients. The PDC metric is recommended for integration into clinical practice to monitor and improve medication adherence.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015256
- 003
- CZ-PrNML
- 005
- 20250731090856.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0325293 $2 doi
- 035 __
- $a (PubMed)40560927
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Tichopád, Aleš $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University, Prague, Czech Republic $1 https://orcid.org/0000000213080877 $7 xx0305052
- 245 10
- $a Statin adherence improves with age and subsequent treatment sequences: A retrospective cohort study using Proportion of Days Covered (PDC) / $c A. Tichopád, G. Donin, J. Žigmond, J. Ráfl, M. Rybář, P. Šedová, M. Vrablík
- 520 9_
- $a BACKGROUND: Dyslipidaemia is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), necessitating effective statin therapy. Despite statins' proven safety and efficacy, adherence remains suboptimal, with significant gaps between clinical practice and guideline recommendations. METHODS: This retrospective cohort study analysed anonymized health administrative claims data from six employee health funds in the Czech Republic, covering approximately 40% of the insured population from January 1, 2017, to December 31, 2020. We identified statin-incident as well as prevalent cohort of patients. Adherence to statin therapy was assessed using the proportion of days covered (PDC) metric, with factors such as age, gender, sequence of use, and treatment intensity considered as modifiers. RESULTS: Among the statin-prevalent cohort (SP, n = 890,180), 83.5% achieved a PDC ≥ 50%, and 61.0% reached a PDC ≥ 80%. In the statin-incident cohort (SI, n = 287,871), a clear trend of increasing adherence with age and medication sequence was observed: in adults aged 18-39 median PDC rose from 84.1% (IQR: 57-100) in the first to 94.7% (IQR: 75.6-100) in the third sequence; in those aged 80 + median PDC rose from 95.0% (IQR: 68.9-100) in the first to 100% (IQR: 78.3-100) in the third sequence. Logistic regression identified age (OR=1.011 per year), female gender (OR=0.896), high-intensity treatment (OR=0.975), and second (OR=1.267) or later treatment sequences (OR=1.704) as significant predictors of adherence (all p < 0.001). CONCLUSION: Adherence to statin therapy improves with subsequent treatment sequences and age. These findings highlight the need for targeted interventions to enhance adherence, particularly among younger patients. The PDC metric is recommended for integration into clinical practice to monitor and improve medication adherence.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a mladý dospělý $7 D055815
- 650 12
- $a dyslipidemie $x farmakoterapie $7 D050171
- 650 12
- $a adherence k farmakoterapii $7 D055118
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Donin, Gleb $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University, Prague, Czech Republic
- 700 1_
- $a Žigmond, Jan $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University, Prague, Czech Republic $1 https://orcid.org/0000000228118241
- 700 1_
- $a Ráfl, Jakub $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University, Prague, Czech Republic $1 https://orcid.org/0000000151029354
- 700 1_
- $a Rybář, Marian $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University, Prague, Czech Republic
- 700 1_
- $a Šedová, Petra $u Department of Internal Medicine and Cardiology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Neurology, International Clinical Research Center, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America $1 https://orcid.org/0000000213790203
- 700 1_
- $a Vrablík, Michal $u 3rd Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000272261926 $7 xx0061419
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 20, č. 6 (2025), s. e0325293
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40560927 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731090851 $b ABA008
- 999 __
- $a ok $b bmc $g 2366241 $s 1252381
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 20 $c 6 $d e0325293 $e 20250625 $i 1932-6203 $m PloS one $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20250708